23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Janux Therapeutics, Inc. › 2025-2026

Janux Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Janux Therapeutics, Inc.’s Form 8-K, filed June 12, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 215Asset managers, any item
  • 1,010Fund votes
  • June 11, 2026Meeting date

Results at a glance

Meeting of June 11, 2026: 4 items on Janux Therapeutics, Inc.’s Form 8-K, filed June 12, 2026: 2 elected · 2 approved.

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Ra Capital Management, L.P. (13D, 19.9%, as of March 10, 2025) · Nantahala Capital (13F, 1.4%, as of September 30, 2026)

Explore Janux Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Janux Therapeutics, Inc.

These tallies are Janux Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Janux Therapeutics, Inc. — official shareholder meeting results, meeting held June 11, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Natasha Hernday 42,850,103---- 4,519,7966,375,023 90%Elected—
Elect Director: Eric Dobmeier 46,279,387---- 1,090,5126,375,023 98%Elected—
2. Ratification of the Selection of Independent Registered Public Accounting Firm 53,560,969113,44670,507 ---- 99.8%Approved—
3. Advisory Vote on Executive Compensation 42,749,1824,574,37646,341 --6,375,023 90%Approved—

Source: Janux Therapeutics, Inc., Form 8-K, filed with the SEC on June 12, 2026 — read the filing on EDGAR.

How asset managers voted at the Janux Therapeutics, Inc. 2025-2026 meeting

215 asset managers disclosed a vote on at least one Janux Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Eric Dobmeier

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 46,279,387WITHHELD: 1,090,512
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: To elect the two nominees for Class II director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders: Eric Dobmeier

Janux Therapeutics, Inc.’s own tally for this item (“Elect Director: Eric Dobmeier”): 46,279,387 for, 1,090,512 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the two persons listed below as Class II directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignat…”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 11,531,316 for, 530,281 withheld, 3 abstained.

FOR
FOR: 11,531,316ABSTAIN: 3WITHHOLD: 530,281
Largest asset managers voting on “To elect the two nominees for Class II director named in the accompanying proxy statement to serve for three-y” at Janux Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,084,5860 30For
Fidelity2,441,0000 00For
BlackRock2,032,6820 00For
State Street1,558,7340 00For
JANUS INVESTMENT FUND688,1870 00For
Charles Schwab354,7550 00For
Federated Hermes00 0295,009Withhold
Bridge Builder Trust15,8520 0130,078Mixed
Allspring124,3300 00For
Hartford112,0040 00For
Northwestern Mutual102,7510 00For
TIAA94,8230 00For
Equitable59,9540 024,880Mixed
Delaware/Macquarie76,6010 00For
QUANTITATIVE MASTER SERIES LLC73,4090 00For
Putnam68,4880 00For
Lincoln Financial65,1060 00For
Dimensional00 062,209Withhold
JPMorgan60,5860 00For
Tema ETF Trust52,1880 00For
Jackson National41,3740 02,277Mixed
MASTER INVESTMENT PORTFOLIO41,9990 00For
ProShares41,6780 00For
Guardian Variable Products Trust39,2840 00For
Pacific Life36,0580 00For

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Elect Director: Natasha Hernday

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%
FOR: 42,850,103WITHHELD: 4,519,796
Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: To elect the two nominees for Class II director named in the accompanying proxy statement to serve for three-year terms until the 2029 Annual Meeting of Stockholders: Natasha Hernday

Janux Therapeutics, Inc.’s own tally for this item (“Elect Director: Natasha Hernday”): 42,850,103 for, 4,519,796 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the two persons listed below as Class II directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignat…”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 11,475,835 for, 585,757 withheld, 8 abstained.

FOR
FOR: 11,475,835ABSTAIN: 8WITHHOLD: 585,757
Largest asset managers voting on “To elect the two nominees for Class II director named in the accompanying proxy statement to serve for three-y” at Janux Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,084,5810 80For
Fidelity2,441,0000 00For
BlackRock2,032,6820 00For
State Street1,556,8760 01,858For
JANUS INVESTMENT FUND688,1870 00For
Charles Schwab354,7550 00For
Federated Hermes295,0090 00For
Bridge Builder Trust145,9300 00For
Allspring00 0124,330Withhold
Hartford112,0040 00For
Northwestern Mutual102,7510 00For
TIAA94,8230 00For
Equitable59,9540 024,880Mixed
Delaware/Macquarie00 076,601Withhold
QUANTITATIVE MASTER SERIES LLC73,4090 00For
Putnam68,4880 00For
Lincoln Financial38,9530 026,153Mixed
Dimensional00 062,209Withhold
JPMorgan60,5860 00For
Tema ETF Trust52,1880 00For
Jackson National41,3740 02,277Mixed
MASTER INVESTMENT PORTFOLIO41,9990 00For
ProShares00 041,678Withhold
Guardian Variable Products Trust2,3000 036,984Mixed
Pacific Life36,0580 00For

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Advisory Vote on Executive Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 6 wordings of this item as funds reported it.

90% Approved · of votes cast

FOR 90%
FOR: 42,749,182AGAINST: 4,574,376

Prior year: 97.9% for (June 11, 2025 meeting) ▼ 7.5 pts

Details: description as filed, official tally, votes by 215 asset managers

Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.

Janux Therapeutics, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 42,749,182 for, 4,574,376 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of our named executive officers as disclosed in the Proxy Statement.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 56 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY ” at Janux Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,078,0446,545 00For
Fidelity2,441,0000 00For
BlackRock2,032,6820 00For
State Street1,556,0552,679 00For
JANUS INVESTMENT FUND688,1870 00For
Charles Schwab354,7550 00For
Federated Hermes0295,009 00Against
Bridge Builder Trust15,852130,078 00Mixed
Allspring124,3300 00For
Hartford0112,004 00Against
Northwestern Mutual0102,751 00Against
TIAA94,8230 00For
Equitable84,8340 00For
Delaware/Macquarie76,6010 00For
QUANTITATIVE MASTER SERIES LLC73,4090 00For
Putnam68,4880 00For
Lincoln Financial65,1060 00For
Dimensional062,209 00Against
JPMorgan60,5860 00For
Tema ETF Trust52,1880 00For
Jackson National41,3742,277 00Mixed
MASTER INVESTMENT PORTFOLIO41,9990 00For
ProShares41,6780 00For
Guardian Variable Products Trust39,2840 00For
Pacific Life36,0580 00For

Fund voting reports, all 56 managers: 11,236,189 for, 810,786 against, 14,574 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 178 asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY ” at Janux Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
RA CAPITAL MANAGEMENT, L.P.11,189,6930 00For
Janus Henderson7,810,8380 00For
Fidelity2,513,5970 00For
BlackRock2,424,05021,328 00For
State Street2,426,63611,916 00For
Prosight Management, LP1,349,4720 00For
GEODE CAPITAL MANAGEMENT, LLC1,160,2410 00For
Logos Global Management LP01,000,000 00Against
ORBIMED ADVISORS LLC983,6000 00For
Wellington0973,505 00Against
Irenic Capital Management LP765,8040 00For
Nantahala Capital Management, LLC579,1690 00For
Alyeska Investment Group, L.P.0465,296 00Against
Federated Hermes0449,413 00Against
Point72436,0950 00For
Deep Track Capital, LP419,2480 00For
Vanguard371,8750 00For
Rock Springs Capital Management LP367,0090 00For
Charles Schwab354,9520 00For
Woodline Partners LP345,4020 00For
Northern Trust228,6934,931 00For
ADAR1 Capital Management, LLC174,0140 00For
Allspring163,5580 00For
Citadel153,7830 00For
ALGERT GLOBAL LLC00 151,5320Abstain

Institutional-manager reports, all 178 managers: 35,705,003 for, 3,852,599 against, 151,532 abstained, 4,197 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the Selection of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.8% Approved · of votes cast

FOR 99.8%
FOR: 53,560,969AGAINST: 113,446

Prior year: 100.0% for (June 11, 2025 meeting) ▼ 0.2 pts

Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2026.

Janux Therapeutics, Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 53,560,969 for, 113,446 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal …”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 57 asset managers below reported 12,047,026 for, 14,574 abstained.

FOR
FOR: 12,047,026ABSTAIN: 14,574
Largest asset managers voting on “TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS OUR INDEPENDE” at Janux Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard3,084,5890 00For
Fidelity2,441,0000 00For
BlackRock2,032,6820 00For
State Street1,558,7340 00For
JANUS INVESTMENT FUND688,1870 00For
Charles Schwab354,7550 00For
Federated Hermes295,0090 00For
Bridge Builder Trust145,9300 00For
Allspring124,3300 00For
Hartford112,0040 00For
Northwestern Mutual102,7510 00For
TIAA94,8230 00For
Equitable84,8340 00For
Delaware/Macquarie76,6010 00For
QUANTITATIVE MASTER SERIES LLC73,4090 00For
Putnam68,4880 00For
Lincoln Financial65,1060 00For
Dimensional62,2090 00For
JPMorgan60,5860 00For
Tema ETF Trust52,1880 00For
Jackson National43,6510 00For
MASTER INVESTMENT PORTFOLIO41,9990 00For
ProShares41,6780 00For
Guardian Variable Products Trust39,2840 00For
Pacific Life36,0580 00For

Showing the 25 largest of 57 asset managers. All 57 are in the interactive database (link above).

Largest Janux Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 60,865,458 shares outstanding at the time of that meeting.

Fund voting reports: top Janux Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 5.07%
2Fidelity 4.01%
3BlackRock 3.34%
4State Street 2.56%
5JANUS INVESTMENT FUND 1.13%
6Charles Schwab 0.58%
7Federated Hermes 0.48%
8Bridge Builder Trust 0.24%
9Allspring 0.20%
10Hartford 0.18%
Institutional-manager reports: top Janux Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS…”, 2025-2026
#Asset manager % of shares outstanding
1RA CAPITAL MANAGEMENT, L.P. 18.38%
2Janus Henderson 12.83%
3Fidelity 4.13%
4BlackRock 4.02%
5State Street 4.01%
6Prosight Management, LP 2.22%
7GEODE CAPITAL MANAGEMENT, LLC 1.91%
8Logos Global Management LP 1.64%
9ORBIMED ADVISORS LLC 1.62%
10Wellington 1.60%

Reported Janux Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Janux Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Entities affiliated with RA Capital Healthcare Fund, L.P.12,396,724 20.37%Proxy statement (DEF 14A), proxy filed April 28, 2026
BlackRock5,433,233 8.93%Form 13F, quarter ended March 31, 2026
Entities affiliated with Janus Henderson Group plc5,350,453 8.79%Proxy statement (DEF 14A), proxy filed April 28, 2026
JANUS HENDERSON GROUP PLC4,196,409 6.89%Schedule 13G, filed May 15, 2026
FMR LLC3,512,384 5.77%Proxy statement (DEF 14A), proxy filed April 28, 2026
Entities affiliated with Prosight3,157,220 5.19%Proxy statement (DEF 14A), proxy filed April 28, 2026
Prosight Management, LP3,150,970 5.18%Schedule 13G, filed February 6, 2026
David Campbell, Ph.D.3,064,039 5.03%Proxy statement (DEF 14A), proxy filed April 28, 2026
Vanguard Group2,906,386 4.78%Form 13F, quarter ended March 31, 2026
FMR (Fidelity)2,535,724 4.17%Form 13F, quarter ended March 31, 2026

Percentages above are of 60,865,458 shares outstanding, as reported by Janux Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Janux Therapeutics, Inc.'s shareholder meeting held June 11, 2026, in the 2025-2026 proxy season, 215 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,010 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS… — Janux Therapeutics, Inc.'s filing reports the proposal as approved, with 90% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Janux Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Janux Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Janux Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Janux Therapeutics (JANX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/janux-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.